Healthcare Professionals

• About DUROLANE
• Classification
• Clinical data
• Benefits of DUROLANE
• Treatment
  • Clinical Procedure
  • Post Treatment
• Algorithms
• Resources
  • Enquiry Form

The Benefits of DUROLANE

Viscosupplementation with hyaluronic acid (HA) is now well established, having been shown to be effective and well tolerated for the long-term management of OA pain in numerous randomised, controlled trials^1,2,3.

DUROLANE is a hyaluronic acid treatment for Osteoarthritis of the knee and hip based upon NASHA technology (Non Animal Stabilised Hyaluronic Acid). It is the only hyaluronic acid treatment currently available as a single intra-articular injection.

One Single Injection

DUROLANE is the first CE marked single injection viscosupplement, and is based upon a proven and patented manufacturing process.

Non Animal Stabilised Hyaluronic Acid (NASHA) dramatically increases the intra-articular residence time of the hyaluronic acid within the joint without compromising physiological compatibility.

DUROLANE can provide up to 6 months pain relief from a single injection.

Safety

NASHA based products have been used within a range of clinical applications for the past 20 years and have consistently proven to be safe and effective.

Additionally DUROLANE has proven safety, offering effective results with less risk of injection related side effects.

The side effect profile has demonstrated equivalence to controls. See Instructions for Use (PDF) for more detailed information.

Non Drug, Non Surgical Treatment

DUROLANE is locally administered directly into the affected joint, and as such is an effective alternative to prescribed drugs or surgical treatment.

> Treatment

References

Ref 1: Recommendations for the medical management of osteoarthritis of the hip and knee. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Arthritis Rheum 2000; 43: 1905-1915.

Ref 2: EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Pendelton A, Arden N, Dougados M, et al. Ann Rheum Dis 2000; 59: 936-944.

Ref 3: Viscosupplementation for the treatment of osteoarthritis of the knee. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G The Cochrane Database of Systematic Reviews 2007 Issue 2